Case Study 20.2 — Wei Zhang and STTR

A composite, illustrative case. Dr. Wei Zhang and the technology are composites built to teach; the STTR structure and rules are real. Verify current specifics at SBIR.gov and the relevant agency.

Why a second case: the STTR path

Case Study 20.1 followed an SBIR company that does its R&D in-house. This case follows the other path — STTR — because many of the most important deep-technology companies are spun out of university labs, and STTR exists precisely for them. Meet Dr. Wei Zhang, a chemistry professor who has invented a novel catalyst in his university lab that could make an industrial chemical process dramatically cleaner and cheaper. Wei wants to commercialize it — but the technology still needs deep, ongoing work that only his lab can do, with its specialized equipment and graduate researchers, and Wei has no intention of leaving his faculty position to run a company full-time. His situation would be impossible under SBIR. It is exactly what STTR was built for.

Decision 1 — Why STTR, not SBIR (Section 20.3)

Wei runs the SBIR-vs-STTR decision and finds STTR fits on every axis that matters to him:

  • The work must happen in the lab. STTR requires a small-business–research-institution partnership and funds the lab's continued role (with its minimum share, commonly ~30%) — so the specialized work stays where it can be done.
  • Wei wants to keep his professorship. STTR uniquely allows the PI not to be primarily employed by the small business, so Wei can serve as the project's PI while remaining a full-time professor. Under SBIR, the PI must be primarily employed by the company — a non-starter for Wei.
  • The company is brand-new. AquaSense (Case 20.1) already had its own engineers; Wei's company is barely formed and has no independent lab. STTR lets the venture lean on the university's capacity while the company is built.

He does not try to choose SBIR and subcontract the majority of the work to the university — the work-share rules forbid it. That is STTR's job, and he uses STTR.

Decision 2 — Setting up the partnership (Sections 20.3, 20.6)

STTR requires real agreements, so Wei works with his university's technology-transfer office early. They negotiate the intellectual-property arrangement (who owns and licenses the invention — typically the university licenses it to the company), the work-share split (meeting STTR's minimums for both the company and the institution), and the roles. This takes time and care — university IP and partnership agreements are not quick — and Wei starts well before the deadline, treating the partnership setup as part of the proposal work, not an afterthought. The partnership and its terms become part of what reviewers evaluate.

Decision 3 — Still both tests (Section 20.4)

STTR changes the structure, not the fundamental demand: Wei must still pass both tests. The technical merit is strong — a genuinely novel catalyst with clear feasibility questions for Phase I. The harder discipline for an academic is the commercial potential: who buys this, how big is the market, who are the incumbent process and competitors, what's the path from lab catalyst to industrial adoption, and how will Phase III be financed? Wei, a chemist by training, deliberately brings in business help — a co-founder with industry and commercialization experience — so the company can make a credible market case and so reviewers see a team that can commercialize, not just invent. This is the same lesson Priya's case taught from the SBIR side: the science alone never suffices.

Decision 4 — The handoff over time

Wei plans the company's evolution. Early on, STTR keeps the inventing lab central while the company is thin. As the company hires its own scientists and builds capacity, Wei anticipates shifting toward SBIR for later work that the company can do in-house — the common trajectory for university spinouts. STTR is the on-ramp from lab to company; SBIR becomes the vehicle once the company can stand on its own.

What this case teaches

  1. STTR is the university-spinout's program. When the inventing lab must stay central and the PI wants to keep a faculty role, STTR's partnership structure and PI rule make possible what SBIR forbids.
  2. The partnership is real work. IP and work-share agreements with the technology-transfer office take time; start early and treat them as part of the proposal.
  3. Both tests still apply. STTR changes the structure, not the demand — an academic founder must build genuine commercial capability (often via a business co-founder) to pass the commercialization test.
  4. STTR → SBIR is a natural arc. Many companies start on STTR to keep the lab involved, then move to SBIR as they build in-house capacity.

🔄 Retrieve: Without rereading, name (a) the two STTR features that made it fit Wei when SBIR could not, and (b) the non-technical capability Wei deliberately added to his team, and why. (Answers above.)